Test 2021-11-15T14:10:19+00:00

Vygoris is a new company in the UK.
We develop sophisticated niche generic pharmaceuticals.

We pride ourselves in being innovative, proactive and experts in the development of complex and difficult to manufacture formulations.
We strive for excellence in all that we do and we aim to offer our clients around the globe high quality pharmaceutical products and comprehensive service.
A young, dynamic and vibrant company, we’re driven by an ambition to deliver results. Our team is continually seeking the next opportunity, through forthcoming patent expirations or new ventures. We look for pharmaceutical products with a degree of complexity, technological difficulty and clinical and manufacturing risk, choosing to work in niche pharmaceutical markets where we can make a truly positive difference to our customers.

Your Content Goes Here
Your Content Goes Here

About Us

Vygoris Ltd is a subsidiary of Substipharm, a privately owned French specialist generics company.
We are launching shortly in the UK with a recently acquired urology product, Mitocin, for use primarily in bladder cancer.
Our aim is to introduce innovative and difficult to manufacture specialist products, in a range of therapy areas.


Vygoris’ first launch in the UK is in bladder cancer. Further information will shortly be available on the Mitocin website.


Contact Us

Any adverse event and product information enquiries should be sent to our third party pharmacovigilance provider:
Tel +44 (0) 1223 402660
Fax: +44 (0) 1223 413689
Email: safety@productlife-group.com

Latest company and product news

March 2019

November 2018

Vygoris / Substipharm announce the full acquisition of the nystatin based product (ready mixed Oral suspension) across Europe from BMS.

June 2018

Vygoris announces distribution agreement with Dr Pfleger GmgH in Germany.

Press Release

April 2018

Vygoris announces exclusive licensing agreement with Verity Pharmaceuticals to offer a safe and steady supply of Mitomycin in Canada.

Press Release.

Jan 18

Vygoris will launch its first product in the UK in the bladder cancer area. Further information will shortly be available on the Mitocin website.

Jan 18

Vygoris will attend the Swiss HLG Winter Conference 28th – 30th January 2018.